[Retracted] Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status

<div>Flow diagram of patient enrollment. NSCLC: non-small-cell lung cancer, LM: leptomeningeal metastasis, CSF: cerebrospinal fluid, <i>EGFR</i>: epidermal growth factor receptor, ALK: anaplastic lymphoma kinase, ROS1: ROS proto-oncogene 1, and TKI: tyrosine kinase inhibitor.</div>

Evidence-Based Complementary and Alternative Medicine

fig1

Figure 1

Figure 1: [Retracted] Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status 

Figure 1 | [Retracted] Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status 